vs
Side-by-side financial comparison of Public Service Enterprise Group (PEG) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $2.9B, roughly 1.3× Public Service Enterprise Group). On growth, Public Service Enterprise Group posted the faster year-over-year revenue change (18.3% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $-408.0M). Over the past eight quarters, Public Service Enterprise Group's revenue compounded faster (2.8% CAGR vs 0.5%).
The Public Service Enterprise Group, Inc. (PSEG) is a publicly traded energy company based in Newark, New Jersey, where it has been based since its founding. It was founded in 1985, with its roots tracing back to 1903.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
PEG vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $3.7B |
| Net Profit | $315.0M | — |
| Gross Margin | — | 31.1% |
| Operating Margin | 17.5% | -5.2% |
| Net Margin | 10.8% | — |
| Revenue YoY | 18.3% | 5.0% |
| Net Profit YoY | 10.1% | — |
| EPS (diluted) | $0.63 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $3.7B | ||
| Q3 25 | $3.2B | $3.7B | ||
| Q2 25 | $2.8B | $3.6B | ||
| Q1 25 | $3.2B | $3.2B | ||
| Q4 24 | $2.5B | $3.5B | ||
| Q3 24 | $2.6B | $3.7B | ||
| Q2 24 | $2.4B | $3.8B | ||
| Q1 24 | $2.8B | $3.7B |
| Q4 25 | $315.0M | — | ||
| Q3 25 | $622.0M | — | ||
| Q2 25 | $585.0M | — | ||
| Q1 25 | $589.0M | — | ||
| Q4 24 | $286.0M | — | ||
| Q3 24 | $520.0M | — | ||
| Q2 24 | $434.0M | — | ||
| Q1 24 | $532.0M | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 17.5% | -5.2% | ||
| Q3 25 | 26.5% | 4.8% | ||
| Q2 25 | 29.1% | 6.5% | ||
| Q1 25 | 24.7% | -88.9% | ||
| Q4 24 | 18.1% | -5.1% | ||
| Q3 24 | 24.3% | 6.0% | ||
| Q2 24 | 24.0% | -6.3% | ||
| Q1 24 | 24.8% | 5.6% |
| Q4 25 | 10.8% | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 11.6% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 19.3% | — |
| Q4 25 | $0.63 | $-0.34 | ||
| Q3 25 | $1.24 | $-0.11 | ||
| Q2 25 | $1.17 | $0.00 | ||
| Q1 25 | $1.18 | $-2.55 | ||
| Q4 24 | $0.57 | $-0.43 | ||
| Q3 24 | $1.04 | $0.08 | ||
| Q2 24 | $0.87 | $-0.27 | ||
| Q1 24 | $1.06 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $132.0M | $1.3B |
| Total DebtLower is stronger | $22.5B | — |
| Stockholders' EquityBook value | $17.0B | $14.7B |
| Total Assets | $57.6B | $37.2B |
| Debt / EquityLower = less leverage | 1.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $132.0M | $1.3B | ||
| Q3 25 | $334.0M | $975.3M | ||
| Q2 25 | $186.0M | $566.4M | ||
| Q1 25 | $894.0M | $755.0M | ||
| Q4 24 | $125.0M | $734.8M | ||
| Q3 24 | $203.0M | $1.9B | ||
| Q2 24 | $113.0M | $917.2M | ||
| Q1 24 | $1.2B | $1.0B |
| Q4 25 | $22.5B | — | ||
| Q3 25 | $22.5B | — | ||
| Q2 25 | $22.6B | — | ||
| Q1 25 | $23.0B | — | ||
| Q4 24 | $21.1B | — | ||
| Q3 24 | $21.4B | — | ||
| Q2 24 | $20.5B | — | ||
| Q1 24 | $21.3B | — |
| Q4 25 | $17.0B | $14.7B | ||
| Q3 25 | $17.0B | $15.2B | ||
| Q2 25 | $16.7B | $15.6B | ||
| Q1 25 | $16.4B | $15.7B | ||
| Q4 24 | $16.1B | $18.6B | ||
| Q3 24 | $16.1B | $19.8B | ||
| Q2 24 | $15.8B | $19.5B | ||
| Q1 24 | $15.7B | $20.0B |
| Q4 25 | $57.6B | $37.2B | ||
| Q3 25 | $56.9B | $37.9B | ||
| Q2 25 | $56.0B | $38.4B | ||
| Q1 25 | $55.6B | $38.5B | ||
| Q4 24 | $54.6B | $41.5B | ||
| Q3 24 | $54.1B | $44.8B | ||
| Q2 24 | $52.4B | $45.3B | ||
| Q1 24 | $52.4B | $47.3B |
| Q4 25 | 1.33× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.30× | — | ||
| Q1 24 | 1.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $721.0M | $815.8M |
| Free Cash FlowOCF − Capex | $-408.0M | $619.3M |
| FCF MarginFCF / Revenue | -14.0% | 16.8% |
| Capex IntensityCapex / Revenue | 38.7% | 5.3% |
| Cash ConversionOCF / Net Profit | 2.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | $26.0M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $721.0M | $815.8M | ||
| Q3 25 | $1.1B | $744.9M | ||
| Q2 25 | $478.0M | $219.7M | ||
| Q1 25 | $1.0B | $535.5M | ||
| Q4 24 | $367.0M | $482.7M | ||
| Q3 24 | $623.0M | $826.5M | ||
| Q2 24 | $482.0M | $379.1M | ||
| Q1 24 | $661.0M | $614.6M |
| Q4 25 | $-408.0M | $619.3M | ||
| Q3 25 | $322.0M | $658.1M | ||
| Q2 25 | $-309.0M | $166.8M | ||
| Q1 25 | $421.0M | $492.9M | ||
| Q4 24 | $-611.0M | $342.3M | ||
| Q3 24 | $-145.0M | $749.5M | ||
| Q2 24 | $-355.0M | $320.3M | ||
| Q1 24 | $-136.0M | $564.8M |
| Q4 25 | -14.0% | 16.8% | ||
| Q3 25 | 10.0% | 17.6% | ||
| Q2 25 | -11.0% | 4.7% | ||
| Q1 25 | 13.1% | 15.2% | ||
| Q4 24 | -24.8% | 9.7% | ||
| Q3 24 | -5.5% | 20.1% | ||
| Q2 24 | -14.7% | 8.5% | ||
| Q1 24 | -4.9% | 15.5% |
| Q4 25 | 38.7% | 5.3% | ||
| Q3 25 | 22.6% | 2.3% | ||
| Q2 25 | 28.1% | 1.5% | ||
| Q1 25 | 19.5% | 1.3% | ||
| Q4 24 | 39.7% | 4.0% | ||
| Q3 24 | 29.1% | 2.1% | ||
| Q2 24 | 34.5% | 1.6% | ||
| Q1 24 | 28.9% | 1.4% |
| Q4 25 | 2.29× | — | ||
| Q3 25 | 1.69× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 1.78× | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 1.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PEG
| PSEG Power Other | $1.1B | 37% |
| Electric Distribution Contracts | $929.0M | 32% |
| Gas Distribution Contracts | $840.0M | 29% |
| Other | $71.0M | 2% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
